FABOMOTIZOLE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21N3O2S.ClH
Molecular Weight	343.872
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC1=CC2=C(C=C1)N=C(N2)SCCN3CCOCC3

InChI

InChIKey=MYSRFAUFQZYTOV-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S.ClH/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18;/h3-4,11H,2,5-10H2,1H3,(H,16,17);1H

HIDE SMILES / InChI

Molecular Formula	C15H21N3O2S
Molecular Weight	307.411
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf
Curator's Comment: description was created based on several sources, including http://pro-pharma.biz/?page_id=171

Fabomotizole (also known as Afobazole) is a selective non-benzodiazepine anxiolytic which was developed in Russia and launched in 2006. The drug is used for the treatment of wide range of diseases: generalized anxious disorders, neurasthenia, adaptation disorders, sleep disorders, for alleviation of withdrawal syndrome. According to the drug label (in Russian), its action is related to the interaction with sigma-1 receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Agonist 2678		5.9 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Generalized anxiety disorder 32 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 1.13607364E12
Neurasthenia 5 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 1.13607364E12
Adjustment disorder 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 1.13607364E12
Insomnia 108 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 1.13607364E12
Withdrawal syndrome 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Palliative	Approved 8429	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 1.13607364E12

PubMed

Title	Date	PubMed
Neuroprotective properties of afobazol in vitro.	2005 Aug	16282999
Neuroprotective effects of afobazol in experimental cerebral hemorrhage.	2005 Nov	16758618
[Effect of afobazole on transmembrane ion currents in mollusk neurons].	2005 Sep-Oct	16277200
Studies of long-term noopept and afobazol treatment in rats with learned helplessness neurosis.	2006 Aug	17369939
[Effect of afobazole on the accumulation of free radical oxidation products and the catalase activity in rats with cerebral ischemia].	2006 Jul-Aug	16995439
[Evidence for the neuroprotective properties of afobazole in experimental model of focal brain ischemia].	2006 Jul-Aug	16995428
[Effect of afobazole on brain-ischemia-induced anxiety in rats].	2006 Mar-Apr	16845930
[Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction].	2006 May-Jun	16878488
[A comparative study of the effect of afobazole on brain monoamine systems in BALB/C and C57BL/6 mice].	2006 Sep-Oct	17153957
[Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole].	2007	18379478
[Pharmacokinetics of afobazole in rats].	2007 Mar-Apr	17523455
Tissue availability of afobazole and its major metabolites in rats.	2007 May	18239776
[Using of aphobazol in the treatment of adaptation disorder in the contract service men, dismissed from the armed forces].	2007 Nov	18306710
In vivo effects of afobazole (2-mercaptobenzimidazole derivative) on the 7,12-dimethylbenz [alpha]anthracene-induced oncogene and suppressor gene expression.	2007 Nov-Dec	18210756
[Administration of afobasol for correction of mental disorders in celiac disease patients].	2008	19105406
[Efficacy of aphobazole in the treatment of anxiety disorders in patients with chronic cerebro-vascular insufficiency].	2008	18800419
Excretion of afobazole and its metabolites with urine and feces in rats.	2008 Apr	19110588
Effect of afobazole on teratogenic activity of cyclophosphamide in rats.	2008 Apr	19110587
Gateways to clinical trials. December 2008.	2008 Dec	19271026
Neuroprotective effect of afobazole on rats with bilateral local photothrombosis of vessels in the prefrontal cortex.	2008 Feb	19023970
[Afobazole metabolism in rats].	2008 Mar-Apr	18488909
[Antimutagenic and antiteratogenic properties of afobazole].	2009 Jan-Feb	19334511
[Specific effects of selective anxiolytic afobazole on the cardiovascular system].	2009 Jan-Feb	19334510
[Afobazole effect on heart rate variability in rats with different behaviors in the "open field" test].	2009 Jan-Feb	19334509
[Effects of afobazole on the stress protein HSP70 level in the brain tissue of rats with global transient ischemia].	2009 Jan-Feb	19334508
[Neuroprotective effects of afobazole in a hemorrhagic stroke model].	2009 Jan-Feb	19334507
[Afobazole influence on antinociceptive properties of morphine].	2009 Jan-Feb	19334506
[Antidepressant properties of afobazole in Porsolt and Nomura tests].	2009 Jan-Feb	19334505
[Afobazole decreases motor side effects induced by haloperidol].	2009 Jan-Feb	19334504
[Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons].	2009 Jan-Feb	19334503
[Neuroreceptor mechanisms of the afobazole effect].	2009 Jan-Feb	19334502
Interaction of afobazole with sigma1-receptors.	2009 Jul	19902093
Effect of afobazole on mitochondrial monoamine oxidase A activity in vitro.	2009 Jul	19902087
[Afobazole effect on cerebral circulation under hemorrhagic stroke model conditions].	2009 Nov-Dec	20095394
Effect of afobazole on DNA damage in patients with systemic lupus erythematosus.	2009 Oct	20396750
[Effectiveness of combined application of ursosan and anxiolytic 2-mercaptobenzimidazole in early stage of cholelithiasis].	2010	20623958
[Afobasol efficacy in a model of vagotonic atrial fibrillation].	2010	20540357
[Afobasol antifibrillation activity in animals with the intact and denervated myocardium].	2010	20540356
[Effects of afobasol in the reperfusion arrhythmia model].	2010	20540355
Neuroprotective properties of afobazole in repeated hemorrhagic stroke modeling in aged rats.	2010 Aug	21113492
Effects of selective anxiolytic afobazole on active caspase-3.	2010 Aug	21113491
[Model study of afobazole distribution in pregnant and lactating female rats and infant rat pups].	2010 Aug	20919552
[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].	2010 Mar	20408420
[Antiarrhythmic properties of afobazole and other 2-mercaptobensimidazole derivatives].	2010 May	20597362
[Cerebrovascular effects of afobazole under conditions of combined disorders of cerebral and coronary circulation].	2010 May	20597361
[Comparative study of the interoceptive effects of afobazole and diazepam].	2010 Oct	21254504
Comparative analysis of tissue availability for afobazole and compound M-11.	2010 Sep	21246091
On the mechanism of antifibrillatory effect of afobazole.	2010 Sep	21246090
Effect of afobazole on genotoxic effects of tobacco smoke in the placenta and embryonic tissues of rats.	2010 Sep	21246089
[Anxiolytic afobazole action self-evaluated by patients with anxiety-asthenic disorders].	2010 Sep	21086645

Patents

Sample Use Guides

In Vivo Use Guide

For adult persons and children it is recommended to use internally, after meal. Usually it is recommended to use 1 tablet (10 mg) trice per day. The maximum daily dose is 60 mg. The period of therapy is 2-4 weeks. According to doctor prescription it is possible to prolong the period up to 3 months.

Route of Administration: Oral

In Vitro Use Guide

Experiments on immortalized hippocampal cell culture of mice showed that afobazole increases the NGF level in a final concentration of 10(-8) M and the BDNF level in final concentrations from 10(-8) to 10(-5) M.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:35:48 UTC 2023` Edited by `admin` on `Fri Dec 15 17:35:48 UTC 2023`
Record UNII	HDO6HX6NZU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FABOMOTIZOLE HYDROCHLORIDE

Common Name

English

AFOBAZOLE MONOHYDROCHLORIDE

Common Name

English

1H-BENZIMIDAZOLE, 5-ETHOXY-2-((2-(4-MORPHOLINYL)ETHYL)THIO)-, MONOHYDROCHLORIDE

Common Name

English

APHOBAZOLE MONOHYDROCHLORIDE

Common Name

English

FABOMOTIZOLE MONOHYDROCHLORIDE

Common Name

English

FABOMOTIZOLE HYDROCHLORIDE [MART.]

Common Name

English

1H-BENZIMIDAZOLE, 6-ETHOXY-2-((2-(4-MORPHOLINYL)ETHYL)THIO)-, HYDROCHLORIDE (1:1)

Systematic Name

English

AFOBAZOL MONOHYDROCHLORIDE

Common Name

English

OBENOXAZINE HYDROCHLORIDE

Common Name

English

SM-346

Code

English

Fabomotizole hydrochloride [WHO-DD]

Common Name

English

FABOMOTIZOLE MONOHYDROCHLORIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28197